文献速递真菌感染细菌感染、耐药与抗菌药物

艾沙康唑与阿尼芬净对烟曲霉的体外相互作用

In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究采用改良EUCAST棋盘微量稀释法及FIC指数和Bliss独立分析,检测艾沙康唑与阿尼芬净对30株烟曲霉(含18株唑类耐药株)的体外协同作用。结果显示对多数野生型和唑类耐药株具协同作用,但TR46/Y121F/T289A突变株在临床可达浓度下无显著获益。

要点

  • 艾沙康唑联合阿尼芬净对多数野生型和唑类耐药烟曲霉体外协同。
  • TR46/Y121F/T289A突变株在临床可达浓度下无显著协同获益。
  • 高唑类耐药地区该联合可能对野生型、唑类耐药及混合感染获益。

核心结论

  • 艾沙康唑与阿尼芬净对多数野生型和唑类耐药烟曲霉分离株体外协同。
  • 对TR46/Y121F/T289A等高艾沙康唑耐药株,联合治疗可能无获益。

研究设计与样本

  • 采用改良EUCAST基于2D(12×8)棋盘肉汤微量稀释比色法(XTT)检测30株烟曲霉,包括18株唑类耐药株。
  • 通过FIC指数分析和Bliss独立分析评估艾沙康唑与阿尼芬净的体外相互作用。

主要发现

  • FICi分析和BI分析均显示,对多数野生型和唑类耐药分离株,艾沙康唑与阿尼芬净呈协同相互作用。
  • 对TR46/Y121F/T289A分离株,在临床可达药物浓度下未观察到联合治疗的显著有益效应。

临床怎么用

  • 在高唑类耐药率地区,该联合可能使野生型疾病、唑类耐药侵袭性曲霉病及混合唑类敏感/耐药感染患者获益。
  • 对由高艾沙康唑耐药分离株(如TR46/Y121F/T289A)所致曲霉病,该联合可能无获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The voriconazole and echinocandin combination has been found to be synergistic in vitro and in vivo against most Aspergillus fumigatus isolates, both with a WT azole phenotype and an azole-resistant phenotype. The interaction between isavuconazole and echinocandins is less well studied. This is especially true for azole-resistant isolates. OBJECTIVES: We investigated the in vitro interaction between isavuconazole and anidulafungin for 30 A. fumigatus isolates including 18 azole-resistant isolates with various isavuconazole resistance phenotypes. METHODS: The isavuconazole/anidulafungin interaction was studied by using an adapted EUCAST-based 2D (12 × 8) chequerboard broth microdilution colorimetric assay using XTT. The interaction was analysed by FIC index (FICi) analysis and Bliss independence (BI) interaction analysis. RESULTS: Both the FICi analysis and the BI analysis showed synergistic interaction between isavuconazole and anidulafungin for the majority of WT and azole-resistant isolates. As we did not see significant beneficial effects of combination therapy in TR46/Y121F/T289A isolates at clinically achievable drug concentrations, it is unlikely that TR46/Y121F/T289A infections would benefit from isavuconazole and anidulafungin combination therapy. CONCLUSIONS: In regions with high azole resistance rates this combination may benefit patients with WT disease, azole-resistant invasive aspergillosis and those with mixed azole-susceptible and azole-resistant infection, but may not be beneficial for aspergillosis due to isolates with high isavuconazole resistance, such as TR46/Y121F/T289A isolates.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Buil JB, Brüggemann RJM, Bedin Denardi L, et al. In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates. J Antimicrob Chemother. 2020. PMID: 32516368. doi:10.1093/jac/dkaa185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。